Issue link: https://www.e-digitaleditions.com/i/1000772
THOMAS ENGINEERING INC. - 575 West Central Rd. Hoffman Estates, IL, 60192 - TEL 800-634-9910 W W W . T H O M A S E N G . C O M THOMAS TABLET PRESS TOOLING In other news, the organization also acquired ExcipientFest from Dwight Mutchler, president of IMCD, an excipient distributor. The yearly exhibition and conference, which launched in 2001, will be renamed Excipient World and will continue to offer high-quality educa- tion for all excipient end-users and provide a marketplace to connect buyers with excipient suppliers. FDA approves first non-opioid treatment for opioid withdrawal symptoms SILVER SPRINGS, MD—The FDA approved Lucemyra (lofexidine hydrochloride) to manage withdrawal symptoms of abrupt opioid discontin- uation in adults. Lucemyra is an oral, selective alpha 2-adrenergic receptor agonist that reduces the release of norepinephrine, a hormone believed to play a role in many symptoms associated with opioid withdrawal. The drug is manufactured by US WorldMeds, Louisville, KY. Madison Dearborn acquires Alcami DURHAM, NC—Alcami, a phar- maceutical CDMO, has agreed to be acquired by Madison Dearborn Partners, a private equity firm based in Chicago, IL. The CDMO offers services such as API development and manufacturing, solid state chem- istry, formulation development, ana- lytical development and testing ser- vices, oral solid dose drug product manufacturing, and packaging and stability services. Alcami's current management team, led by chief exec- utive officer, president, and chair- man, Dr. Stephan Kutzer, will con- tinue to guide the company. The transaction is expected to be com- pleted by the end of 2018. US FDA approves new medicines more quickly than European counterpart NEW HAVEN, CT—The FDA reviews and approves new medicines in a shorter timeframe than the European Medicines Agency (EMA), according to a report by researchers at Yale, Brigham and Women's Tablets & Capsules July 2018 9